We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures

By LabMedica International staff writers
Posted on 14 Sep 2026

Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. More...

Misordered or overused assays can complicate infection metrics, trigger penalties, and strain laboratory resources. Aligning test selection with clinical need is therefore a priority for quality improvement and patient safety. A new resource outlines how health systems can build an institution-specific business case for diagnostic stewardship.

The Society for Healthcare Epidemiology of America (SHEA) has published “Business Case for Diagnostic Stewardship: A Practical Guide from the Society for Healthcare Epidemiology of America (SHEA) Diagnostic Stewardship Special Interest Group” in Antimicrobial Stewardship & Healthcare Epidemiology (ASHE). The guide provides health care leaders with a framework to develop institution-specific business cases for diagnostic stewardship programs, including financial models for five high‑impact interventions. It is intended to strengthen patient outcomes, improve quality metrics, and reduce health care costs.

The resource defines diagnostic stewardship as ensuring the right test is ordered for the right patient at the right time, with results appropriately interpreted. It details five common opportunities for improvement: optimizing Clostridioides difficile testing, optimizing urine culture use, de‑implementing unnecessary procalcitonin testing, optimizing respiratory pathogen panel use, and optimizing blood culture use. For each area, the guide outlines implementation strategies, projected financial impact, and practical examples that hospitals can adapt to their settings.

As an example of potential value, the authors estimate that a representative 200‑bed community hospital implementing all five interventions could achieve approximately $2.5 million to $2.8 million in annual laboratory and clinical savings. Depending on baseline performance, improved quality metrics could also reduce Centers for Medicare & Medicaid Services (CMS) Hospital‑Acquired Condition penalties by an estimated $200,000 to $600,000. The interventions may additionally improve publicly reported health care–associated infection metrics and hospital reputation.

The publication appears as diagnostic excellence gains national attention. The Centers for Disease Control and Prevention (CDC) Core Elements of Hospital Diagnostic Excellence identify diagnostic stewardship as a key strategy for improving diagnosis while advancing health care quality, safety, and value‑based care. SHEA’s Diagnostic Stewardship Special Interest Group developed the guide to support health care executives, laboratory leaders, infection prevention professionals, antimicrobial stewardship teams, and clinicians.

“Health care leaders know that every investment must improve both patient care and operational performance. This framework helps hospitals evaluate and implement diagnostic stewardship in ways that improve clinical outcomes, strengthen quality metrics and demonstrate measurable value,” said Sarah E. Turbett, M.D., senior author of the paper.

Related Links
The Society for Healthcare Epidemiology of America


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.